Recent Updates
Recently added Catalysts

EYU688

Phase 2

Dengue | Small molecule | Infectious Disease |Novartis AG|Last Updated: Mar 24, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment108
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06006559A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue FeverPHASE2 RECRUITING 108 — — Feb 20, 2024Jan 15, 2027Mar 24, 202623 Brazil, Colombia +4
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Viremia reduction (viral load reduction (VLR) on log scale) at 48 hours post treatment start
From predose to 48 hours post treatment start

Efficacy assessment of EYU688. It will allow to quantify the viremia reduction at 48 hours post treatment start from baseline.

Secondary Endpoints
Time from fever onset to start of the first 48 hours period during which the oral temperature remained below 37.5℃
From fever onset to Day 15
Time from fever onset to the first of two consecutive negative viremia by PCR
From fever onset to Day 15
Area under the log-transformed viremia curve (AUC) from the first dose to Day 15
From fever onset to Day 15
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
EYU688EXPERIMENTALEYU688 administered by oral route
PlaceboPLACEBO_COMPARATORMatching placebo
Interventions
NameTypeDescription
EYU688DRUGEYU688 administered by oral route
PlaceboDRUGMatching placebo administered orally as capsules
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 60 Years
SexALL
Healthy VolunteersNo
Study Sites23

Inclusion Criteria: * Male or female, 18 - 60 years old (inclusive). * History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection: * Nausea or vomiting. * Presence of rash, aches or pains including headache, muscle or joint pain. * Onset of fever ≤ 48 ...

Countries:BrazilColombiaIndiaMalaysiaSingaporeVietnam
Unlock Eligibility Criteria
Competitive Landscape -Dengue 10 trials
CompanyTickerTrialsLead PhaseDrugs
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK5PHASE3Tetravalent Dengue Vaccine, TDV
Novartis AG Sponsored ADRNVS1PHASE2EYU688
Sanofi SA Sponsored ADRSNY1 — Undisclosed
Abbott LaboratoriesABT1 — Undisclosed
Danaher CorporationDHR1 — Undisclosed
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
MEDIUMMay 26, 2026NCT06006559primaryCompletionDate: changed
LOWMay 24, 2026NCT06006559studyFirstPostDate: changed